Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relenza Dear Doctor Letter In EU Follows U.S. Advisory

Executive Summary

Glaxo Wellcome is warning European prescribers about potential side effects with Relenza one week after similar concerns were raised by FDA.
Advertisement

Related Content

Glaxo Wellcome Ziagen
Glaxo Wellcome Ziagen
Glaxo Wellcome Relenza
Glaxo Wellcome Relenza
FDA Counterdetailing Influenza Treatments Relenza and Tamiflu
FDA Counterdetailing Influenza Treatments Relenza and Tamiflu
Relenza Use In U.K. For 2000 Season Will Await Four Ongoing Glaxo Trials
Advertisement
UsernamePublicRestriction

Register

PS035534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel